249 related articles for article (PubMed ID: 16931788)
1. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
Zadelaar AS; Boesten LS; Jukema JW; van Vlijmen BJ; Kooistra T; Emeis JJ; Lundholm E; Camejo G; Havekes LM
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol.
Kooistra T; Verschuren L; de Vries-van der Weij J; Koenig W; Toet K; Princen HM; Kleemann R
Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2322-30. PubMed ID: 16873727
[TBL] [Abstract][Full Text] [Related]
3. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
van der Hoorn JW; Jukema JW; Havekes LM; Lundholm E; Camejo G; Rensen PC; Princen HM
Br J Pharmacol; 2009 Apr; 156(7):1067-75. PubMed ID: 19220285
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
[TBL] [Abstract][Full Text] [Related]
5. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
6. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
[TBL] [Abstract][Full Text] [Related]
7. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.
van der Hoorn JW; Kleemann R; Havekes LM; Kooistra T; Princen HM; Jukema JW
J Hypertens; 2007 Dec; 25(12):2454-62. PubMed ID: 17984667
[TBL] [Abstract][Full Text] [Related]
8. [Peroxisome proliferator-activated receptor α/γ agonist tesaglitazar stabilizes atherosclerotic plaque in diabetic low density lipoprotein receptor knockout mice].
Zhang BC; Li XK; Che WL; Li WM; Hou L; Wei YD; Xu YW
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Feb; 41(2):143-9. PubMed ID: 23710746
[TBL] [Abstract][Full Text] [Related]
9. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.
Chira EC; McMillen TS; Wang S; Haw A; O'Brien KD; Wight TN; Chait A
Atherosclerosis; 2007 Nov; 195(1):100-9. PubMed ID: 17214992
[TBL] [Abstract][Full Text] [Related]
10. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome.
Hartvigsen K; Binder CJ; Hansen LF; Rafia A; Juliano J; Hörkkö S; Steinberg D; Palinski W; Witztum JL; Li AC
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):878-85. PubMed ID: 17255537
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels.
Raffai RL; Loeb SM; Weisgraber KH
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):436-41. PubMed ID: 15591220
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.
Oumouna-Benachour K; Hans CP; Suzuki Y; Naura A; Datta R; Belmadani S; Fallon K; Woods C; Boulares AH
Circulation; 2007 May; 115(18):2442-50. PubMed ID: 17438151
[TBL] [Abstract][Full Text] [Related]
13. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
[TBL] [Abstract][Full Text] [Related]
14. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.
Hellmold H; Zhang H; Andersson U; Blomgren B; Holland T; Berg AL; Elebring M; Sjögren N; Bamberg K; Dahl B; Westerberg R; Dillner B; Tugwood J; Tugwood J; Roberts R; Lundholm E; Camejo G; Skånberg I; Evans J
Toxicol Sci; 2007 Jul; 98(1):63-74. PubMed ID: 17468185
[TBL] [Abstract][Full Text] [Related]
15. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
[TBL] [Abstract][Full Text] [Related]
16. Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.
Sharma S; Sowjanya A; Kumari M; Suryaprakash R; Cynthia G; Suresh J; Chakrabarti R
Life Sci; 2006 Dec; 80(3):235-44. PubMed ID: 17014868
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.
Verreth W; Ganame J; Mertens A; Bernar H; Herregods MC; Holvoet P
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):922-8. PubMed ID: 16456093
[TBL] [Abstract][Full Text] [Related]
18. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
[TBL] [Abstract][Full Text] [Related]
19. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
Schuster H; Fagerberg B; Edwards S; Halmos T; Lopatynski J; Stender S; Birketvedt GS; Tonstad S; Gause-Nilsson I; Halldórsdóttir S; Ohman KP;
Atherosclerosis; 2008 Mar; 197(1):355-62. PubMed ID: 17631296
[TBL] [Abstract][Full Text] [Related]
20. Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis.
Liu R; Hojjati MR; Devlin CM; Hansen IH; Jiang XC
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):190-6. PubMed ID: 17038631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
